Education
About Us
Working with TipRanks
Follow Us
Sight Sciences (SGHT)
NASDAQ:SGHT
SGHT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.03 - $8.45
Previous CloseN/A
Volume59.09K
Average Volume (3M)189.91K
Market Cap
$159.22M
Enterprise Value$104.91M
Total Cash (Recent Filing)$120.36M
Total Debt (Recent Filing)$40.36M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
May 08, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding51,695,686
10 Day Avg. Volume174,886
30 Day Avg. Volume189,905
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.54
Enterprise Value/Ebitda-2.20
Forecast
1Y Price Target
$3.20Price Target Upside3.90% Upside
Rating ConsensusHold
Number of Analyst Covering7
---
Sight Sciences News
PremiumCompany Announcements
Sight Sciences Appoints Gerhard F. Burbach to Board
PremiumCompany Announcements
Sight Sciences’ Earnings Call: Cautious Optimism Amid Challenges
PremiumCompany Announcements
Sight Sciences Reports 2024 Results and 2025 Outlook---
Bulls Say, Bears Say
Bulls Say
Financial FlexibilitySight maintains a solid $120 million cash position, which enables flexibility for ongoing product launches, market access efforts, and further R&D investments.
Product Growth PotentialTearCare was discussed as a significant product with potential for growth and market impact.
Product PipelineThe company's pipeline was highlighted as a promising aspect during the conference.
Bears Say
Coverage RestrictionsFive Medicare administrative contractors finalized LCDs restricting coverage for glaucoma procedures using multiple MIGS, causing an industry-wide headwind.
Revenue Guidance2025 revenue guidance is below consensus due to the impact of LCDs on OMNI's volume outlook.
Tariffs And CostsTariffs were mentioned as a potential challenge for the company, implying possible cost implications.
---
Ownership Overview
33.73% Insiders
5.39% Mutual Funds
<0.01% Other Institutional Investors
54.49% Public Companies and
Individual Investors
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $2.03 and its highest was $8.45 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $159.22M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is May 08, 2025 which is in 5 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on Mar 05, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.204 by -$0.026.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.28.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 51,695,686 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.204. Following the earnings report the stock price went up 2.893%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
---
Sight Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.20 (3.90% Upside)
$3.20 (3.90% Upside)
Hedge Fund Trend
Decreased
By 11.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $94.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.90%
12-Months-Change
Fundamentals
Return on Equity
-49.59%
Trailing 12-Months
Asset Growth
-14.29%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
---
SGHT Company Deck
---
SGHT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call depicted a mixed outlook. While Sight Sciences achieved revenue growth and significant reductions in cash usage, challenges related to Medicare LCDs, a decline in TearCare revenue, and tariff impacts were notable. Clinical advancements and pipeline developments offer positive future potential. Overall, the sentiment reflects cautious optimism amid current challenges.Read More>---
SGHT Stock 12 Month Forecast
Average Price Target
$3.20
▲(3.90% Upside)
Technical Analysis
---